¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-05-13

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-05-13
±³À°ÀÏÀÚ : 2022-05-13
±³À°Àå¼Ò : °æÁÖ È­¹éÄÁº¥¼Ç¼¾ÅÍ  
±³À°ÁÖÁ¦ : Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ
´ã´çÀÚ : ÀÌ¿¬ÁÖ
¿¬¶ôó : 02-714-9071  
À̸ÞÀÏ : diabetes@kams.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 1300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 170,000¿ø      
ºñ°í È¸¿ø ÀÇ»ç: 120,000¿ø ºñȸ¿ø ÀÇ»ç: 170,000¿ø ȸ¿ø ºñÀÇ»ç: 70,000¿ø ºñȸ¿ø ºñÀÇ»ç: 120,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 08:30~08:50 Initial combination therapy for T2DM; for whom, what is the optimal combination?  ¹ÚÁ¤È¯(ÇѾçÀÇ´ë ³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 09:00~09:25 Effect of SGLT2 inhibitors in heart failure with preserved ejection fraction  ½ÉÁö¿µ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 09:25~09:50 Cardiovascular and renal outcomes with Finerenone with type 2 diabetes with CKD  È²Çö¼®(°æÈñÀÇ´ë ½ÅÀå³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 09:50~10:15 Post-hoc analysis of AMPLITUDE-O study (CVOT study of Efpeglenatide)  ¹é½ÂÀç(Çѹ̾àÇ° ½Å¾àÀӻ󰳹ߺ»ºÎ) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 10:15~10:40 Safety and efficacy of GLP-1/GIP dual agonists in patients with type 2 diabetes  Á¶¿µ¹Î(¼­¿ïÀÇ´ë ³»°ú) 
Åä·Ð 05-13 °æÁÖ HICO Room1 10:40~11:00 Panel discussion  Á¤Ã¢ÈñÀ̻󿭼­¹ÌÇýÀ±ÁöÈñ(¿ï»êÀÇ´ë ³»°ú°æÈñÀÇ´ë ³»°ú¼øõÇâÀÇ´ë ³»°úÀü³²ÀÇ´ë ³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 11:30~12:10 Tirzepatide: a dual GIP and GLP-1 receptor agonist in development for the treatment of type 2 diabetes, obesity and non-alcoholic steatohepatitis  Juan Pablo Frias(Velocity Clinical Research USA) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 12:10~13:20 Intermittently scanned CGM: clinical evidence and practical tips  Áø»ó¸¸(¼º±Õ°üÀÇ´ë ³»°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 14:50~15:30 Sirtuin 6 as a multitasking player in immune cell differentiation and metabolic diseases  ¹Úº´Çö(ÀüºÏÀÇ´ë »ýÈ­ÇкÐÀÚ»ý¹°Çб³½Ç) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 15:50~16:20 Self-care solutions for GDM patients  ¹ÚÇýÀº(°æÈñÀÇ·á¿ø °£È£°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 16:20~16:50 Self-care solutions for children and adolescents with diabetes  À̽ÂÈñ(°æºÏ´ëÇб³¾î¸°À̺´¿ø °£È£°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 16:50~17:20 Self-care solutions for young diabetic patients  ±è¼±¿µ(»ï¼º¼­¿ïº´¿ø °£È£°ú) 
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 17:20~17:50 Self-care solutions for elderly diabetic patients  ¹Ú¼±¿µ(°è¸í´ëÇб³ µ¿»êÀÇ·á¿ø °£È£°ú) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-05-13""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022³âµµ ÀÇ°ú´ëÇÐ ±³À°°úÁ¤ °³¹ß°ú Æò°¡ ¿öÅ©¼ó(2ÀÏÂ÷) : 2022-05-14
´ÙÀ½±Û 2022³âµµ ÀÇ°ú´ëÇÐ ±³À°°úÁ¤ °³¹ß°ú Æò°¡ ¿öÅ©¼ó(1ÀÏÂ÷) : 2022-05-13
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20910 ¼­¿ï 2024³â Á¦14ȸ °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ³»°ú ¿¬¼ö°­Á : 2024-07-07 0 4 2024-05-28
20909 °æ±â ¾ÆÁÖ´ëÇб³º´¿ø Á¤Çü¿Ü°ú 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-07-07 0 8 2024-05-28
20908 ¼­¿ï Á¦19Â÷ ´ëÇѸðÀ¯¼öÀ¯ÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-07-07 0 9 2024-05-28
20907 °æ±â Á¦2Â÷ ´ëÇѽŰæ¹æ»ç¼±¼ö¼úÇÐȸ Á¤±âÇмú´ëȸ : 2024-07-06 0 8 2024-05-28
20906 °æ±â Á¦ 5ȸ ¿À»ê½ÃÀÇ»çȸ Çмú´ëȸ : 2024-07-06 0 5 2024-05-28
20905 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Á¦3ȸ ¾Æ»êµÎ°æºÎ Æ÷·³ : 2024-07-06 0 8 2024-05-28
20904 ¼­¿ï 2024³â Á¦2ȸ °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ¼øȯ±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-06 0 9 2024-05-28
20903 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day3) : 2024-07-06 0 9 2024-05-28
20902 ¼­¿ï ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ 2024³â ÇÏ°è NeurocrItical Care Essence (NICE) ¾ÆÄ«µ¥¹Ì : 2024-07-06 0 5 2024-05-28
20901 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø Á¦10ȸ ºÎ½Å¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 2 2024-05-28
20900 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day2) : 2024-07-05 0 4 2024-05-28
20899 ¼­¿ï ÀÓ»ó¼ú±â±³À°¿¬±¸È¸ Á¦16ȸ ÀÓ»ó¼ú±â ¿¬¼ö°­Á : 2024-07-04 0 8 2024-05-28
20898 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 3 2024-05-28
20897 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 4 2024-05-28
20896 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 5 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷